Peter Hutt - Salarius Pharmaceuticals Non-Executive Independent Director
| SLRX Stock | USD 0.53 0.01 1.85% |
Director
Mr. Peter Barton Hutt, L.L.B., L.L.M., is the NonExecutive Independent Director of the company., since March 2014. Mr. Hutt is a senior counsel at the law firm of Covington Burling LLP and was an attorney with that firm since 1960. He served as Chief Counsel for the U.S. Food and Drug Administration from 1971 through 1975. Mr. Hutt is a member of the Institute of Medicine of the National Academy of Sciences and teaches a course on Food and Drug Law each winter term at Harvard Law School. He coauthored the casebook used to teach Food and Drug Law and has published numerous papers on the subject. Mr. Hutt is a member of the board of directors of DBV Technologies, Q Therapeutics, Xoma Ltd., BIND Therapeutics, Inc., Concert Pharmaceuticals Inc., and several privatelyheld life sciences companies. During the last five years, Mr. Hutt also served as a member of the board of directors of Celera Genomics, Introgen Therapeutics, Inc. and Ista Pharmaceuticals, Inc. Mr. Hutt received his B.A., magna cum laude, from Yale University, his L.L.B. from Harvard University and his L.L.M. from New York University. Mr. Hutt qualifications to sit on the board include his 50 years of experience and expertise in food and drug regulation, including his service at the U.S. Food and Drug Administration and at Covington Burling LLP, and his experience serving on other boards of directors in the biotechnology industry since 2014.
| Age | 83 |
| Tenure | 10 years |
| Address | 2450 Holcombe Boulevard, Houston, TX, United States, 77021 |
| Phone | 832 834 6992 |
| Web | https://www.salariuspharma.com |
Salarius Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.759) % which means that it has lost $0.759 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6007) %, meaning that it created substantial loss on money invested by shareholders. Salarius Pharmaceuticals' management efficiency ratios could be used to measure how well Salarius Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2 in 2024. Return On Capital Employed is likely to drop to -2.56 in 2024. At this time, Salarius Pharmaceuticals' Other Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 14.2 M in 2024, whereas Total Assets are likely to drop slightly above 6.3 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jeffrey Johnson | Jaguar Animal Health | 45 | |
| Donald Olds | Acasti Pharma | 57 | |
| John Micek | Jaguar Animal Health | 64 | |
| JeanMarie Canan | Acasti Pharma | 57 | |
| Folkert Kamphuis | Jaguar Animal Health | 57 | |
| Akihisa Akao | Pulmatrix | 59 | |
| Katherine Crewe | Acasti Pharma | N/A | |
| Amit Munshi | Pulmatrix | 50 | |
| Steven Gillis | Pulmatrix | 65 | |
| Kermit Anderson | Adial Pharmaceuticals | 67 | |
| Scott Rocklage | Pulmatrix | 60 | |
| Terrance McGuire | Pulmatrix | 61 | |
| Gregory French | Pulmatrix | 53 | |
| Michael Higgins | Pulmatrix | 55 | |
| Tony Goodman | Adial Pharmaceuticals | 60 | |
| Ari Azhir | Jaguar Animal Health | 69 | |
| Gregory Divis | Jaguar Animal Health | 50 | |
| Jonathan Siegel | Jaguar Animal Health | 44 | |
| Richard Schottenfeld | Acasti Pharma | N/A | |
| Richard Conley | Pulmatrix | 63 | |
| Valier Boivin | Acasti Pharma | N/A | |
Management Performance
| Return On Equity | -1.6 | ||||
| Return On Asset | -0.76 |
Salarius Pharmaceuticals Leadership Team
Elected by the shareholders, the Salarius Pharmaceuticals' board of directors comprises two types of representatives: Salarius Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Salarius. The board's role is to monitor Salarius Pharmaceuticals' management team and ensure that shareholders' interests are well served. Salarius Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Salarius Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Cermak, Vice President - Research & Development | ||
| Marc Kozin, Non-Executive Independent Director | ||
| Christoph Westphal, Chairman of the Board | ||
| David Arthur, President CEO | ||
| Michelle Stacy, Director | ||
| Scott Jordan, CFO | ||
| Kathie Lindemann, COO | ||
| Mark CPA, Executive CFO | ||
| Elizabeth Woo, Senior Vice President Investor Relations and Corporate Communications | ||
| Roger Tung, Director | ||
| Daniela Santiesteban, Director Program | ||
| Stuart Randle, Non-Executive Independent Director | ||
| John Sculley, Non-Executive Independent Director | ||
| David MBA, President CEO | ||
| Jeffrey Capello, Director | ||
| Peter Hutt, Non-Executive Independent Director | ||
| MPH MD, Senior Development |
Salarius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Salarius Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.6 | ||||
| Return On Asset | -0.76 | ||||
| Current Valuation | (3.3 M) | ||||
| Shares Outstanding | 4.78 M | ||||
| Shares Owned By Insiders | 6.08 % | ||||
| Shares Owned By Institutions | 5.50 % | ||||
| Number Of Shares Shorted | 115.61 K | ||||
| Price To Book | 0.41 X | ||||
| Price To Sales | 18.12 X | ||||
| Gross Profit | (15.84 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Salarius Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Salarius Pharmaceuticals' short interest history, or implied volatility extrapolated from Salarius Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
When determining whether Salarius Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Salarius Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Salarius Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Salarius Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Salarius Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Salarius Stock analysis
When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Salarius Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Salarius Pharmaceuticals. If investors know Salarius will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Salarius Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.84) | Quarterly Revenue Growth (1.00) | Return On Assets (0.76) | Return On Equity (1.60) |
The market value of Salarius Pharmaceuticals is measured differently than its book value, which is the value of Salarius that is recorded on the company's balance sheet. Investors also form their own opinion of Salarius Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Salarius Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Salarius Pharmaceuticals' market value can be influenced by many factors that don't directly affect Salarius Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Salarius Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Salarius Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Salarius Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.